Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indian-based company Cadila Healthcare has received tentative approval from the FDA to market simvastatin tablets for the treatment of cholesterol.
Subscribe to our email newsletter
The drug, a lipid-lowering agent which helps to prevent a stroke or heart attack, falls in the cardiovascular segment of the market, the company noted. Cadila said it would market the drug through its subsidiary Zydus Pharmaceuticals.
The branded sales of simvastatin (marketed as Zocor by Merck & Co.) in the US, was estimated at $4.6 billion.
This marks the 18th approval of a new drug application for Cadila since the commencement of filing process in FY 2003-04.